cheapest beats by dre pan>)--Regulatory News:

pan>)--Regulatory News:
“These are very stimulating study results. We are currently planning to take
the p53-activating ingredient APR-246 forward into a Phase II-trial around
epithelial ovarian cancer with mutated p53 in combination with
regular chemotherapy.”
Aprea today announced optimistic data from a completed Stage I/II clinical
study with its investigational medication APR-246. The results from the study
have been published in the Journal with Clinical Oncology. Based on the
positive data, Aprea is planning to advance APR-246 into a Phase II
proof-of-concept study inside ovarian cancer. Aprea is a Karolinska
Development (STO:KDEV) stock portfolio company,new beats by dre.
In the Phase I/II-trial, on the rise , doses of APR-246 were administered
as monotherapy to 22 individuals with advanced blood- or right index finger length
during up to four continuous days. Dose limiting accumulation was shown at
plasma televisions levels well above forecasted therapeutic plasma levels. Case study
also demonstrated dose-proportional and time-independent
pharmacokinetics pertaining to APR-246 over the dose range researched.
The results from the study are published in the Journal of
Clinical Oncology. In addition to reporting which the drug was well
accepted, the authors conclude with the study that APR-246 induces
organic effects and that there are cases of clinical effects on cancer
burden. One patient by using advanced blood cancer demonstrated a 50 percent
reduction in the sheer numbers of blast cells in the bone tissue marrow.
Ulf Bjrklund, CEO, Aprea:
These are very stimulating study results. We are right now planning to take
the p53-activating mixture APR-246 forward into a Phase II-trial with
epithelial ovarian cancer with mutated p53 in combination with
traditional chemotherapy.
In the new proof-of-concept review, APR-246 will be administered in
conjunction with the reintroduction of a carboplatin-based regimen. Your
striking synergistic effect amongst APR-246 and the very active and
frequently used cancer product carboplatin have been observed in
pre-clinical experiments.
Torbjrn Bjerke, CEO, Karolinska Improvement:
This is indeed promising info. Although it was primarily a security
trial, the data indicates that APR-246 comes with an anti-tumor effect. APR-246
was well accepted and, importantly, the safety account is different
from traditional cytostatic prescription drugs. With these new results we can easily see a
clear path in advance for APR-246, especially in carboplatin-resistant
patients.
To your EDITORS
About Aprea
Aprea AB is a Swedish biotech company focusing on finding and
development of novel anticancer compounds targeting the tumor suppressor
health proteins p53. Aberrations in p53 are common in many a variety of cancer forms
and are associated with increased resistance to standard chemotherapy
and thus poor prognosis. Aprea is usually a Karolinska Development AB (publ)
portfolio business. The other main owners usually are stersjstiftelsen,
Praktikerinvest and KCIF Co-Investment Fund KB. To learn more,
please visit www.aprea.com
.
With regards to Karolinska Development AB
Karolinska Development goals to create value for investors, patients, and
researchers by simply developing innovations from top class science into
products that may be sold or out-licensed with high earnings. The
business model is to: Find the most commercially attractive healthcare
innovations; DEVELOP innovations concise where the greatest return
for investment can be achieved; and COMMERCIALIZE the particular innovations through
the profit of companies or out-licensing of items. An exclusive deal
flow agreement with Karolinska Institutet Innovations AB, as well as
other cooperation agreements using leading Nordic universities, delivers
a nonstop flow of innovations. Nowadays, the portfolio consists of Thirty five
projects, of which 15 are in clinical development. For more information,
kindly visit www,cheapest beats by dre.karolinskadevelopment.com.
Karolinska Development is listed on NASDAQ OMX. Karolinska Development
is usually necesary to disclose the information provided here pursuant to
the Securities Marketplaces Act.
This information was delivered by Cision http://www.cisionwire.com
Information Resource: Business Wire



September Eighteenth, 2012 @ 04:31pm